Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. PharmaSat - Wikipedia
PharmaSat - Wikipedia
From Wikipedia, the free encyclopedia

PharmaSat
PharmaSat undergoing preflight testing
Mission typeBiological research
OperatorNASA
COSPAR ID2009-028B Edit this at Wikidata
SATCAT no.35002
WebsitePharmaSat
Mission duration6 months (planned)
3 years, 2 months, 25 days (final)
Spacecraft properties
Bus3U CubeSat
ManufacturerNASA Ames Space Center
Launch mass4.5 kg (9.9 lb)
PowerSolar cells and batteries
Start of mission
Launch date19 May 2009, 23:55 UTC[1][2]
RocketMinotaur I
Launch siteMARS, Pad 0B
ContractorOrbital Sciences
End of mission
Decay date14 August 2012
Orbital parameters
Reference systemGeocentric orbit[3]
RegimeLow Earth orbit
Perigee altitude428 km (266 mi)
Apogee altitude466 km (290 mi)
Inclination40.4°
Period93.52 minutes

PharmaSat was a nanosatellite developed by NASA Ames Research Center which measured the influence of microgravity upon yeast resistance to an antifungal agent. As a follow on to the GeneSat-1 mission, the Ames Small Spacecraft Division conducted the PharmaSat mission in collaboration with industry and local universities.[4]

PharmaSat was the first nanosatellite to implement biological science guided by its Principal Investigator. The mission was designed to aid the development of medicines or techniques to enable long-term crewed space travel and habitation.

Background

[edit]

The PharmaSat mission builds upon technology demonstrated by GeneSat-1, which used a CubeSat to study microfluidics and optics in the space environment. It was designed to provide life-support, growth, monitoring, and analysis capabilities for microorganisms.

Based, like GeneSat-1, around a three-unit CubeSat platform; PharmaSat was designed to accomplish five functions in an autonomous free-flying platform:[4]

  1. Provide life support and environmental control for growth of the yeast strain in 48 independent microwells;
  2. Dose the growing yeast with antifungal agent at the appropriate point on the growth curve with three distinct, well-defined dosage levels, plus a zero-dose control;
  3. Track the population of the yeast via optical density of each microwell before, during and after antifungal administration;
  4. Determine well-by-well yeast viability at multiple, well-defined times after antifungal administration using a colorimetric reagent, Alamar Blue;
  5. Telemeter the resulting population and viability data to Earth, along with system status data.

Operations

[edit]

PharmaSat was launched at 23:55 UTC on 19 May 2009 aboard a Minotaur I launch vehicle from Pad 0B at the Mid-Atlantic Regional Spaceport on Wallops Island. PharmaSat was flown as a secondary payload co-manifested with the US Air Force Air Force Research Laboratory's TacSat-3 spacecraft.

PharmaSat was successfully inserted into a low Earth orbit at approximately 459 km (285 mi) above the Earth, following which it was activated and began transmitting radio signals to two ground control stations. The primary ground station at SRI International in Menlo Park, California, transmitted mission data from the satellite to its operators, while a second station was located at Santa Clara University, whose Robotic Systems Laboratory was responsible for operating the satellite.

After establishing contact the satellite was commanded to initiate its experiment, which lasted 96 hours. Once the experiment began, PharmaSat relayed data in near real-time for up to six months.[5] PharmaSat also carried an amateur radio beacon, with a frequency of 437.465 megahertz, which broadcast spacecraft telemetry. Amateur radio operators were asked to collect data from the spacecraft and provide it to the operators via the Mission Dashboard website.[6]

PharmaSat decayed from orbit and reentered the atmosphere on 14 August 2012.

See also

[edit]
  • Spaceflight portal
  • List of CubeSats

References

[edit]
  1. ^ "Minotaur launch delayed again". Retrieved 11 May 2009.
  2. ^ "Launch Log". Jonathan's Space Report. Retrieved 3 January 2014.
  3. ^ "Satellite Catalog". Jonathan's Space Report. Retrieved 3 January 2014.
  4. ^ a b "PharmaSat Nanosatellite" (PDF). 1 April 2009. Archived from the original (PDF) on 21 January 2022. Retrieved 15 October 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ "Robotics Systems Lab - School of Engineering - Santa Clara University". Archived from the original on 3 May 2009. Retrieved 15 October 2021.
  6. ^ "PharmaSat Mission Dashboard". Archived from the original on 3 May 2009. Retrieved 3 May 2009.
  • v
  • t
  • e
← 2008
Orbital launches in 2009
2010 →
January
  • USA-202 / Orion 6
  • Ibuki, Kukai, SDS-1, Sohla-1
  • Koronas-Foton
February
  • Omid
  • NOAA-19
  • Progress M-66
  • Ekspress-AM44, Ekspress-MD1
  • Hot Bird 10, NSS-9, Spirale-A, Spirale-B
  • OCO
  • Telstar 11N
  • Raduga-1
March
  • Kepler
  • STS-119 (ITS S6)
  • GOCE
  • USA-203
  • Soyuz TMA-14
April
  • Eutelsat W2A
  • USA-204
  • Kwangmyŏngsŏng-2
  • Compass-G2
  • RISAT-2, ANUSAT
  • SICRAL 1B
  • Yaogan 6
  • Kosmos 2450
May
  • USA-205
  • Progress M-02M
  • STS-125
  • Herschel, Planck
  • ProtoStar 2
  • TacSat-3, PharmaSat, AeroCube-3, HawkSat-1, CP6
  • Meridian 2
  • Soyuz TMA-15
June
  • LRO, LCROSS
  • MEASAT-3a
  • GOES 14
  • Sirius FM-5
July
  • TerreStar-1
  • Kosmos 2451, Kosmos 2452, Kosmos 2453
  • RazakSAT
  • STS-127 (JEM-EF, AggieSat 2, BEVO-1, Castor, Pollux)
  • Kosmos 2454, Sterkh No.11L
  • Progress M-67
  • DubaiSat-1, Deimos-1, UK-DMC 2, Nanosat-1B, AprizeSat-3, AprizeSat-4
August
  • AsiaSat 5
  • USA-206
  • JCSAT-RA, Optus D3
  • STSat-2A
  • STS-128 (Leonardo MPLM)
  • Palapa-D
September
  • USA-207 / PAN
  • HTV-1
  • Meteor-M No.1, BLITS, Sterkh-2, SumbandilaSat, UGATUSAT, Universitetsky-Tatyana-2
  • Nimiq 5
  • Oceansat-2, Rubin 9.1, Rubin 9.2, BeeSat-1, UWE-2, ITU-pSat1, SwissCube-1
  • USA-208 / STSS-Demo 1, USA-209 / STSS-Demo 2
  • Soyuz TMA-16
October
  • Amazonas-2, COMSATBw-1
  • WorldView-2
  • Progress M-03M
  • USA-210
  • Thor 6, NSS-12
November
  • SMOS, PROBA-2
  • Progress M-MIM2 (Poisk)
  • Shijian 11-01
  • STS-129 (ExPRESS-1, ExPRESS-2)
  • Kosmos 2455
  • Intelsat 14
  • Eutelsat W7
  • IGS Optical 3
  • Intelsat 15
December
  • USA-211
  • Yaogan 7
  • Kosmos 2456, Kosmos 2457, Kosmos 2458
  • Yaogan 8, Xi Wang 1
  • Helios IIB
  • Soyuz TMA-17
  • DirecTV-12
Launches are separated by dots ( • ), payloads by commas ( , ), multiple names for the same satellite by slashes ( / ).
Crewed flights are underlined. Launch failures are marked with the † sign. Payloads deployed from other spacecraft are (enclosed in parentheses).
Retrieved from "https://teknopedia.ac.id/w/index.php?title=PharmaSat&oldid=1268464068"
Categories:
  • Spacecraft launched in 2009
  • CubeSats
  • Spacecraft launched by Minotaur rockets
  • Spacecraft which reentered in 2012
Hidden categories:
  • Source attribution
  • Use American English from October 2021
  • All Wikipedia articles written in American English
  • Use dmy dates from October 2021

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id